UTHRUnited Therapeutics Corporation
Price
+32%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality mixed, no red flags, price roughly fair, growth steady, the market undecided.
Most of our PH products were initially approved to treat only PAH. In March 2021, Nebulized Tyvaso was approved to treat PH-ILD in addition to PAH. In May 2022, we also obtained FDA approval of Tyvaso DPI to treat both PAH and PH-ILD. We are engaged in further research and development of additional indications for Nebulized Tyvaso to treat certain fibrotic lung conditions underlying PH-ILD. For further details, see Research and Development below.
In the company’s own words · 10-K filed Feb 25, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
United Therapeutics Corporation (UTHR) reported revenue of $783M in Q2 2026 (quarter ended Jun 30, 2026), down 1.9% from the same quarter a year earlier. That came with a gross margin of 87% and net income of $333M (43% of revenue). For the full year FY2025, revenue was $3.18B (+11% year on year) and net income $1.33B. Its largest product in Q2 2026 was Tyvaso DPI at $327M, 42% of the disclosed total, well ahead of Remodulin at 16%. The next results filing is expected around Oct 28, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 8, 2026On September 8, 2026, United Therapeutics Corporation (the Company ) entered into an accelerated share repurchase agreement (the ASR Agreement ) with Citibank, N.A. ( Citi ) to repurchase approximately $477.6 million in the aggregate of the Company’s common stock ( Common Stock ) under the Company’s previously …Material agreement entered · Form 8-K
- Aug 5, 2026United Therapeutics Corporation Reports Second Quarter 2026 Financial Results.Earnings release · press release
- Jul 23, 2026On July 22, 2026, the Board of Directors (the Board ) of United Therapeutics Corporation (the Company ), acting upon the recommendation of its Nominating and Governance Committee, increased the size of the Board to 13 members and appointed Victor Dzau, M.D., to serve as a member of the Board.Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $783.3MThe company’s own SEC segment disclosure.
- Tyvaso DPI$326.6M42%
- Remodulin$126.3M16%
- Nebulized Tyvaso$126.0M16%
- Orenitram$125.7M16%
- Unituxin$65.2M8%
- Product And Service Other$6.8M1%
- Other (1)$6.7M1%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Drug Manufacturers, Specialty & Generic
Ranks #2 of 41 by RyuScore